Experience of 5‐aminosalicylate nephrotoxicity in the United Kingdom

Aim : To study 5‐aminosalicylate nephrotoxicity in patients with inflammatory bowel disease in the UK.

[1]  Hubert G M Leufkens,et al.  5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. , 2004, Gastroenterology.

[2]  M. Pirmohamed,et al.  Monitoring drug treatment , 2003, BMJ : British Medical Journal.

[3]  H. Izzedine,et al.  Primary chronic interstitial nephritis in Crohn's disease. , 2002, Gastroenterology.

[4]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[5]  B. B. Scott,et al.  Monitoring for drug side‐effects in inflammatory bowel disease , 2002 .

[6]  A. Muller,et al.  Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy , 2001, Alimentary pharmacology & therapeutics.

[7]  K. Fellermann,et al.  Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5‐ASA use , 2001, Alimentary pharmacology & therapeutics.

[8]  P. J. Kelly,et al.  Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.

[9]  Corrigan,et al.  Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease , 2000, Alimentary pharmacology & therapeutics.

[10]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[11]  P. Stevens,et al.  Late onset interstitial nephritis associated with mesalazine treatment , 1998, BMJ.

[12]  E. Losada,et al.  Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. , 1998, Clinical nephrology.

[13]  C. Buzio,et al.  Mesalazine-associated interstitial nephritis: twice in the same patient. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  M. World,et al.  Mesalazine-associated interstitial nephritis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Reynolds,et al.  Nephrotoxicity associated with olsalazine. , 1996, The American journal of medicine.

[16]  P. Thuluvath,et al.  Mesalazine induced interstitial nephritis. , 1994, Gut.

[17]  N. Madias,et al.  Serum creatinine as an index of renal function: new insights into old concepts. , 1992, Clinical chemistry.

[18]  E. Masson,et al.  Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. , 1992, Gut.

[19]  Mehta Rp.  Acute interstitial nephritis due to 5-aminosalicylic acid , 1990 .

[20]  R. White.  Time to scrap creatinine clearance? , 1986, British medical journal.

[21]  C. Swartz,et al.  Creatinine clearance and glomerular filtration rate. , 1972, British medical journal.

[22]  B. Scott,et al.  Review article: monitoring for drug side-effects in inflammatory bowel disease. , 2002, Alimentary Pharmacology and Therapeutics.

[23]  M. De Vos.  Clinical pharmacokinetics of slow release mesalazine. , 2000, Clinical pharmacokinetics.

[24]  K. Koch,et al.  Interstitial nephritis associated with 5-aminosalicylic acid. , 1994, Nephron.